Teprotumumab, a fully human monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), is an approved targeted therapy for thyroid eye disease (TED). Teprotumumab-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results